Research programme: cardiovascular therapeutics - Xenon Pharmaceuticals/Merck & Co
Latest Information Update: 28 Dec 2022
Price :
$50 *
At a glance
- Originator Merck & Co; Xenon Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 28 Dec 2022 Discontinued - Preclinical for Cardiovascular disorders in Canada (unspecified route)
- 28 Dec 2022 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Canada